Non-small cell lung cancer, version 1.2020: Featured updates to the NCCN guidelines

David S. Ettinger, Douglas E. Wood, Charu Aggarwal, Dara L. Aisner, Wallace Akerley, Jessica R. Bauman, Ankit Bharat, Debora S. Bruno, Joe Y. Chang, Lucian R. Chirieac, Thomas A. D'Amico, Thomas J. Dilling, Michael Dobelbower, Scott Gettinger, Ramaswamy Govindan, Matthew A. Gubens, Mark Hennon, Leora Horn, Rudy P. Lackner, Michael LanutiTiciana A. Leal, Jules Lin, Billy W. Loo, Renato G. Martins, Gregory A. Otterson, Sandip P. Patel, Karen L. Reckamp, Gregory J. Riely, Steven E. Schild, Theresa A. Shapiro, James Stevenson, Scott J. Swanson, Kurt W. Tauer, Stephen C. Yang, Kristina Gregory, Miranda Hughes

Research output: Contribution to journalArticlepeer-review

568 Scopus citations

Abstract

The NCCN Guidelines for Non-Small Cell Lung Cancer (NSCLC) address all aspects of management for NSCLC. These NCCN Guidelines Insights focus on recent updates in immunotherapy. For the 2020 update, all of the systemic therapy regimens have been categorized using a new preference stratification system; certain regimens are now recommended as "preferred interventions," whereas others are categorized as either "other recommended interventions" or "useful under certain circumstances".

Original languageEnglish
Pages (from-to)1464-1472
Number of pages9
JournalJNCCN Journal of the National Comprehensive Cancer Network
Volume17
Issue number12
DOIs
StatePublished - 2019

Fingerprint

Dive into the research topics of 'Non-small cell lung cancer, version 1.2020: Featured updates to the NCCN guidelines'. Together they form a unique fingerprint.

Cite this